Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in Japan

Mari Shirotani, Tatsuo Kurokawa, Koji Chiba

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The number of worldwide and Asian multiregional clinical trials (MRCTs) submitted for Japanese New Drug Applications increased markedly between 2009 and 2013, with an increasing number performed for simultaneously submission in the USA, EU, and Japan. Asian studies accounted for 32% of MRCTs (14/44 studies) and had comparatively small sample sizes (<500 subjects). Moreover, the number of Japanese subjects in Asian studies was 2.1- to 13.4-fold larger than the sample size estimated using the method described in Japanese MRCT guidelines, whereas the ratio for worldwide studies was 0.05- to 4.9-fold. Before the introduction of this guidelines, bridging or domestic clinical development strategies were used as the regional development strategy in accordance with ICH E5 guidelines. The results presented herein suggest that Asian studies were conducted when the drug had already been approved in the US/EU, when phase 3 clinical trials were not be planned in the USA/EU, when there was insufficient knowledge of ethnic differences in drug efficacy and safety, or when Caucasian data could not be extrapolated to the Japanese population. New strategies with Asian studies including the Japanese population could be conducted instead of Japanese domestic development strategy.

Original languageEnglish
Pages (from-to)753-764
Number of pages12
JournalJournal of Clinical Pharmacology
Volume54
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Japan
Clinical Trials
Guidelines
Sample Size
Pharmaceutical Preparations
Phase III Clinical Trials
Population
Safety

Keywords

  • Asian studies
  • globalization of clinical trials
  • multiregional clinical trial
  • regulatory science

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)

Cite this

Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in Japan. / Shirotani, Mari; Kurokawa, Tatsuo; Chiba, Koji.

In: Journal of Clinical Pharmacology, Vol. 54, No. 7, 2014, p. 753-764.

Research output: Contribution to journalArticle

Shirotani, Mari ; Kurokawa, Tatsuo ; Chiba, Koji. / Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in Japan. In: Journal of Clinical Pharmacology. 2014 ; Vol. 54, No. 7. pp. 753-764.
@article{d26eadf6207d426ba279f850dcd5e56c,
title = "Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in Japan",
abstract = "The number of worldwide and Asian multiregional clinical trials (MRCTs) submitted for Japanese New Drug Applications increased markedly between 2009 and 2013, with an increasing number performed for simultaneously submission in the USA, EU, and Japan. Asian studies accounted for 32{\%} of MRCTs (14/44 studies) and had comparatively small sample sizes (<500 subjects). Moreover, the number of Japanese subjects in Asian studies was 2.1- to 13.4-fold larger than the sample size estimated using the method described in Japanese MRCT guidelines, whereas the ratio for worldwide studies was 0.05- to 4.9-fold. Before the introduction of this guidelines, bridging or domestic clinical development strategies were used as the regional development strategy in accordance with ICH E5 guidelines. The results presented herein suggest that Asian studies were conducted when the drug had already been approved in the US/EU, when phase 3 clinical trials were not be planned in the USA/EU, when there was insufficient knowledge of ethnic differences in drug efficacy and safety, or when Caucasian data could not be extrapolated to the Japanese population. New strategies with Asian studies including the Japanese population could be conducted instead of Japanese domestic development strategy.",
keywords = "Asian studies, globalization of clinical trials, multiregional clinical trial, regulatory science",
author = "Mari Shirotani and Tatsuo Kurokawa and Koji Chiba",
year = "2014",
doi = "10.1002/jcph.273",
language = "English",
volume = "54",
pages = "753--764",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "7",

}

TY - JOUR

T1 - Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in Japan

AU - Shirotani, Mari

AU - Kurokawa, Tatsuo

AU - Chiba, Koji

PY - 2014

Y1 - 2014

N2 - The number of worldwide and Asian multiregional clinical trials (MRCTs) submitted for Japanese New Drug Applications increased markedly between 2009 and 2013, with an increasing number performed for simultaneously submission in the USA, EU, and Japan. Asian studies accounted for 32% of MRCTs (14/44 studies) and had comparatively small sample sizes (<500 subjects). Moreover, the number of Japanese subjects in Asian studies was 2.1- to 13.4-fold larger than the sample size estimated using the method described in Japanese MRCT guidelines, whereas the ratio for worldwide studies was 0.05- to 4.9-fold. Before the introduction of this guidelines, bridging or domestic clinical development strategies were used as the regional development strategy in accordance with ICH E5 guidelines. The results presented herein suggest that Asian studies were conducted when the drug had already been approved in the US/EU, when phase 3 clinical trials were not be planned in the USA/EU, when there was insufficient knowledge of ethnic differences in drug efficacy and safety, or when Caucasian data could not be extrapolated to the Japanese population. New strategies with Asian studies including the Japanese population could be conducted instead of Japanese domestic development strategy.

AB - The number of worldwide and Asian multiregional clinical trials (MRCTs) submitted for Japanese New Drug Applications increased markedly between 2009 and 2013, with an increasing number performed for simultaneously submission in the USA, EU, and Japan. Asian studies accounted for 32% of MRCTs (14/44 studies) and had comparatively small sample sizes (<500 subjects). Moreover, the number of Japanese subjects in Asian studies was 2.1- to 13.4-fold larger than the sample size estimated using the method described in Japanese MRCT guidelines, whereas the ratio for worldwide studies was 0.05- to 4.9-fold. Before the introduction of this guidelines, bridging or domestic clinical development strategies were used as the regional development strategy in accordance with ICH E5 guidelines. The results presented herein suggest that Asian studies were conducted when the drug had already been approved in the US/EU, when phase 3 clinical trials were not be planned in the USA/EU, when there was insufficient knowledge of ethnic differences in drug efficacy and safety, or when Caucasian data could not be extrapolated to the Japanese population. New strategies with Asian studies including the Japanese population could be conducted instead of Japanese domestic development strategy.

KW - Asian studies

KW - globalization of clinical trials

KW - multiregional clinical trial

KW - regulatory science

UR - http://www.scopus.com/inward/record.url?scp=84901985853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901985853&partnerID=8YFLogxK

U2 - 10.1002/jcph.273

DO - 10.1002/jcph.273

M3 - Article

C2 - 24496890

AN - SCOPUS:84901985853

VL - 54

SP - 753

EP - 764

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 7

ER -